Inhibition of key mediators of tumour angiogenesis has culminated in the clinical application of Avastin, a humanised monoclonal antibody binding soluble VEGF-A, thus stopping interaction with its receptors (Ferrara et al, 2004; Hurwitz et al, 2004). Here, VEGFA is linked to neoplasm.